
Loading, please wait...

Loading, please wait...

Research into PAICS breast cancer metastasis has revealed a crucial mechanism that drives tumor spread. Breast cancer remains a significant clinical challenge globally and in India. Therefore, identifying key regulatory factors like PAICS is essential for improving patient outcomes. Recent multi-omics analyses show that PAICS acts as a metabolic regulator. It specifically modulates the epithelial-mesenchymal transition (EMT) process, which is a hallmark of metastatic progression.
Metastasis involves a complex series of molecular changes where cancer cells lose their epithelial traits. Consequently, they acquire mesenchymal characteristics. These traits allow them to migrate and invade other tissues effectively. Study results demonstrate that PAICS knockdown significantly reduces the expression of mesenchymal markers like N-cadherin and Vimentin. Meanwhile, this process increases E-cadherin levels. Since E-cadherin is vital for cell-to-cell adhesion, its restoration suppresses the invasive potential of breast cancer cells.
Furthermore, PAICS expression correlates with the infiltration of various immune cell subsets. This correlation suggests that PAICS does not only affect tumor cells directly. It also alters the immune microenvironment to favor tumor survival. By integrating machine learning algorithms and miRNA expression profiles, researchers have constructed a robust regulatory network. This network highlights how PAICS serves as both a prognostic biomarker and a potential therapeutic target in clinical settings.
The identification of PAICS as a key regulator provides a new avenue for targeted therapy. Because it promotes metastasis by modulating both EMT and the immune microenvironment, inhibiting PAICS could potentially halt disease progression. Future clinical trials may focus on PAICS inhibitors to complement existing treatment regimens. Ultimately, these findings offer hope for more personalized and effective strategies in managing advanced breast cancer.
PAICS acts as a key regulator of the epithelial-mesenchymal transition (EMT). It promotes the migration and invasion of breast cancer cells by altering specific protein expressions.
Higher levels of PAICS expression are generally associated with poorer survival rates in patients. This is because the enzyme facilitates metastatic spread and modifies the immune response within the tumor.
Yes, because PAICS promotes tumor progression, researchers view it as a promising therapeutic target. Knocking down this gene has been shown to suppress the aggressive behavior of cancer cells in laboratory settings.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Guo J et al. Integrative multi-omics analysis identifies PAICS as a key regulator of epithelial-mesenchymal transition in breast cancer metastasis. Discov Oncol. 2026 Apr 14. doi: 10.1007/s12672-026-04968-4. PMID: 41979850.
Huo A, Xiong X. PAICS as a potential target for cancer therapy linking purine biosynthesis to cancer progression. Life Sci. 2023 Oct 15;331:122070. doi: 10.1016/j.lfs.2023.122070.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


New multi-omics research identifies PAICS as a key regulator of epithelial-mesenchymal transition (EMT) and immune microenvironment in breast cancer metasta...
4 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today